What is Solid Biosciences?
Solid Biosciences is a life sciences company dedicated to developing gene therapy treatments for devastating rare diseases. Their portfolio includes SGT-003 for Duchenne muscular dystrophy, SGT-501 for CPVT, and AVB-401 for BAG3-mediated dilated cardiomyopathy, alongside other assets targeting fatal cardiac conditions. The company emphasizes a patient-focused approach, leveraging expertise in science, technology, and disease management to improve patient lives.
How much funding has Solid Biosciences raised?
Solid Biosciences has raised a total of $455M across 3 funding rounds:
Stock Offering
$125M
Share Placement
$90M
Stock/Share Issuance
$240M
Stock Issuance/Offering (2018): $125M, investors not publicly disclosed
Share Placement (2020): $90M led by Perceptive Advisors, Boxer Capital, Ikarian Capital, RA Capital Management, Suvretta Capital Management, Bain Capital, Aspire Capital Fund, and EcoR1 Capital
Stock/Share Issuance (2026): $240M, investors not publicly disclosed
Key Investors in Solid Biosciences
Perceptive Advisors
Perceptive Advisors is an investment firm focused on funding innovative healthcare and life sciences technologies, managing significant assets to support biotech advancements.
RA Capital Management
RA Capital Management is a multi-stage investment manager specializing in healthcare and life science companies, with a focus on drug development and a growing interest in climate technologies.
Bain Capital
Bain Capital is a global private investment firm with a broad platform that includes venture capital and growth equity, known for its strategic and operational value-add services to portfolio companies.
What's next for Solid Biosciences?
With this substantial strategic investment, Solid Biosciences is poised to accelerate the development and potential commercialization of its promising gene therapy candidates. The company's focus on rare and often fatal diseases positions it as a key player in the gene therapy space. Future endeavors will likely involve advancing clinical trials, expanding manufacturing capabilities, and potentially forging new partnerships to broaden the reach of its therapeutic innovations. The sustained backing from prominent investors signals strong confidence in Solid Biosciences' scientific approach and its potential to address significant unmet medical needs.
See full Solid Biosciences company page
